tag big-pharma 
PharmExec
MARCH 29, 2024
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
pharmaphorum
SEPTEMBER 15, 2020
Companies like prescription glasses firm Warby Parker, shoe brand Rothy’s and tele-dentistry’s SmileDirectClub have grown up in today’s digitally native environment and can offer some key pointers for pharma. As part of this, a number of big pharma companies are also racing to develop a safe and effective vaccine for the coronavirus.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
AUGUST 17, 2020
N o one industry is ever quite like another, but there are some valuable lessons for pharma marketing from examining how the financial sector uses technology, builds brands on social channels and approaches digital content. Nevertheless, the advent of COVID-19 is forcing pharma, and many other sectors, to make some radical changes.
Pharmaceutical Technology
JULY 14, 2022
Due to the high price tags associated with these speciality medicines, innovators have naturally favoured big markets with high GDP such as the US and EU-5 (Germany, France, Spain, Italy, and the UK). Go-to-market strategies. The choice of where to launch an orphan drug is an important and difficult decision.
Pharmaceutical Technology
FEBRUARY 22, 2023
The patent battle between Amgen and Sanofi over their cholesterol-lowering antibodies has divided big pharma in the past months. Both drugs come with a high price tag. This case has broader implications for pharma as an industry, which explains the interest from other businesses.
pharmaphorum
DECEMBER 2, 2020
Few companies embody the term ‘pharma giant’ as much as Pfizer. This expertise in fermentation and large-scale pharmaceutical production put Pfizer in good stead when in 1941 the US government appealed to the pharma industry for support in producing penicillin for the war effort. The era of mega-mergers.
pharmaphorum
JUNE 2, 2022
Evaluate expects five big pharma companies to be reliant on orphan drugs to provide 20% or more of their sales by 2026, with Johnson & Johnson topping the list at an estimated 39% of all sales. By 2026, this would mean that orphan drug sales will account for 20% of all prescription drug sales. Raising questions.
Expert insights. Personalized for you.
52 
Let's personalize your content